Keven Lothert

Dr. Keven Lothert

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Biotechnology
Verified
Journal Article
Closed access
KLKeven Lothert
Keven Lothert
FPFelix Pagallies
Felix Pagallies
FEFriederike Eilts
Friederike Eilts
ASArabi Sivanesapillai
Arabi Sivanesapillai
MHMartin Hardt
Martin Hardt
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff

6 May 2022 in Expert Review of Vaccines
Verified
Journal Article
Closed access
KLKeven Lothert
Keven Lothert
FEFriederike Eilts
Friederike Eilts
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
Effective cell-based production processes of virus particles are the foundation for the global availability of classical vaccines, gene therapeutic vectors, and viral oncolytic treatments. Their pr...

1 November 2020 in Journal of Biotechnology
Verified
Journal Article
Closed access
KLKeven Lothert
Keven Lothert
FPFelix Pagallies
Felix Pagallies
TFThomas Feger
Thomas Feger
RARalf Amann
Ralf Amann
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff

1 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KLKeven Lothert
Keven Lothert
AOAnna Offersgaard
Anna Offersgaard
APAnne F. Pihl
Anne F. Pihl
CMChristian K. Mathiesen
Christian K. Mathiesen
TJTanja B. Jensen
Tanja B. Jensen
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
There is a large unmet need for a prophylactic hepatitis C virus (HCV) vaccine to control the ongoing epidemic with this deadly pathogen. Many antiviral vaccines employ whole viruses as antigens. For HCV, this approach became feasible following the development of infectious cell culture systems for virus production. However, the lack of efficient downstream processes (DSP) for HCV purification poses a roadblock for the development of a whole virus vaccine. Using cell culture-derived genotype 1a HCV we developed a scalable and efficient DSP train, employing commonly used clarification and ultrafiltration techniques, followed by two membrane-based chromatography steps. For virus capture, steric exclusion chromatography using cellulose membranes was established, resulting in a virtually complete virus recovery with > 99% protein and 84% DNA depletion. Virus polishing was achieved by sulphated cellulose membrane adsorbers with ~ 50% virus recovery and > 99% protein and 90% DNA depletion. Additional nuclease digestion resulted in 99% overall DNA depletion with final DNA concentrations of 2 ng/mL. Process results were comparable for cell culture-derived HCV of another major genotype (5a). This study provides proof-of-concept for establishment of an efficient and economically attractive DSP with potential application for production of an inactivated whole virus vaccine against HCV for human use.

1 January 2020 in Journal of Virological Methods
Verified
Journal Article
Closed access
KLKeven Lothert
Keven Lothert
GSGundula Sprick
Gundula Sprick
FBFelix Beyer
Felix Beyer
GLGuiliano Lauria
Guiliano Lauria
Peter CzermakPeter Czermak
Peter Czermak
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff

30 August 2023 in Membranes
Verified
Journal Article
Open access
PDF file
KLKeven Lothert
Keven Lothert
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
Several chromatographic approaches have been established over the last decades for the production of pharmaceutically relevant viruses. Due to the large size of these products compared to other biopharmaceuticals, e.g., proteins, convective flow media have proven to be superior to bead-based resins in terms of process productivity and column capacity. One representative of such convective flow materials is membranes, which can be modified to suit the particular operating principle and are also suitable for economical single-use applications. Among the different membrane variants, affinity surfaces allow for the most selective separation of the target molecule from other components in the feed solution, especially from host cell-derived DNA and proteins. A successful membrane affinity chromatography, however, requires the identification and implementation of ligands, which can be applied economically while at the same time being stable during the process and non-toxic in the case of any leaching. This review summarizes the current evaluation of membrane-based affinity purifications for viruses and virus-like particles, including traditional resin and monolith approaches and the advantages of membrane applications. An overview of potential affinity ligands is given, as well as considerations of suitable affinity platform technologies, e.g., for different virus serotypes, including a description of processes using pseudo-affinity matrices, such as sulfated cellulose membrane adsorbers.